NEWS - Manufacturing

Atlanta has scored a major cancer therapeutics company, Dendreon Corporation, which  plans a $70 million investment in South Fulton County. The Seattle-based biotechnology company will locate a new manufacturing facility in Union City.
The company expects to manufacture PROVENGE® (sipuleucel-T) for patients with advanced prostate cancer. PROVENGE is currently under review by the FDA, and should the product receive approval, the manufacturing plant could generate several hundred new biotechnology jobs in the Atlanta region.
According to Gov. Sonny Perdue’s office, “Hosting the 2009 BIO International Convention in May introduced biotechnology companies like Dendreon Corporation to Georgia’s business assets. Our state’s world-class healthcare institutions and hospitals enable companies like Dendreon to conduct clinical research and engage in product development while benefiting from the vast scientific resources that Georgia has to offer,” he said in a prepared statement.
Dendreon plans to locate in a 160,000-sq. ft. facility at the Majestic Airport Center in South Fulton County. Dendreon plans to launch PROVENGE from its existing facility in Morris Plains, N.J. and ramp up manufacturing capacity at its facilities in Union City and in California, according to the company.
The company is traded on the Nasdaq Global Market under the symbol DNDN.

< Prev		Next >